Arcus Biosciences, Inc.

3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
United States

NextGen Class of 2017
Show jobs for this employer

184 articles with Arcus Biosciences, Inc.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 33,950 shares of the Company’s common stock at an exercise price per share of $25.70, which was the closing price on September 8, 2022, and restricted stock units to acquire a total of 16,975 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. announced that, in connection with the appointment of the Company’s new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company’s Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company’s common stock at an exercise price per share of $26.00.

  • Arcus Biosciences announced that its management team will participate in the following upcoming investor conferences.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 22,100 shares of the Company’s common stock at an exercise price per share of $27.35, which was the closing price on August 8, 2022, and restricted stock units to acquire a total of 11,050 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022.

  • Arcus Biosciences, Inc. (NYSE:RCUS), today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline update on its six clinical-stage molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b), HIF-2a and PD-1 – across multiple common cancers.

  • Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a virtual fireside chat at the upcoming 13th Annual Wedbush PacGrow Healthcare Conference.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 10,200 shares of the Company’s common stock at an exercise price per share of $26.19 which was the closing price on July 25, 2022, and restricted stock units to acquire a total of 5,100 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 34,500 shares of the Company’s common stock at an exercise price per share of $28.78, which was the closing price on July 8, 2022, and restricted stock units to acquire a total of 17,250 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 22,850 shares of the Company’s common stock at an exercise price per share of $24.98, which was the closing price on June 23, 2022, and restricted stock units to acquire a total of 11,425 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted sixteen new employees options to purchase a total of 35,050 shares of the Company’s common stock at an exercise price per share of $23.62, which was the closing price on June 8, 2022, and restricted stock units to acquire a total of 17,525 shares of the Company’s common stock.

  • Arcus Biosciences (NYSE:RCUS), announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fifteen new employees options to purchase a total of 49,650 shares of the Company’s common stock at an exercise price per share of $19.08, which was the closing price on May 23, 2022, and restricted stock units to acquire a total of 21,725 shares of the Company’s common stock.

  • iTeos and GSK Mull Future of Anti-TIGIT Candidate After Genentech Flop

    Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.

  • Arcus Biosciences, Inc. (NYSE:RCUS), today reported financial results for the first quarter ended March 31, 2022 and provided a pipeline update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across multiple common cancers.

  • Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. markets close on Monday, May 9, 2022.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 29,050 shares of the Company’s common stock at an exercise price per share of $27.31, which was the closing price on April 25, 2022, and restricted stock units to acquire a total of 14,525 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 28,900 shares of the Company’s common stock at an exercise price per share of $33.70, which was the closing price on April 8, 2022, and restricted stock units to acquire a total of 14,450 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eleven new employees options to purchase a total of 30,950 shares of the Company’s common stock at an exercise price per share of $32.98, which was the closing price on March 23, 2022, and restricted stock units to acquire a total of 15,475 shares of the Company’s common stock.

  • Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 61,000 shares of the Company’s common stock at an exercise price per share of $33.03 which was the closing price on March 8, 2022, and restricted stock units to acquire a total of 30,500 shares of the Company’s common stock.